去纤苷是什么类型的药物,治疗效果怎么样？

Hepatic veno-occlusive disease (HVOD) is a swelling of the endothelial cells of the liver lobules and hepatic veins caused by vascular stenosis or occlusion, leading to lumen stenosis or occlusion, resulting in intrahepatic post-sinusoidal portal hypertension. In the acute stage, hepatomegaly, jaundice, and ascites occur, and more than half of the patients can recover. 20% of patients died of liver failure in the acute stage, and a few patients developed cirrhosis and portal hypertension. HVOD is a rare disease with non-specific clinical manifestations, and treatment is often delayed due to untimely diagnosis or misdiagnosis. (Defibrotide) is a multi-component biochemical drug developed by the Italian company Gentium SpA. It is produced from pig small intestinal mucosal genomic DNA through controlled depolymerization. Currently, the drug has a relatively good effect on HVOD. So, what type of drug is defibrotide and what is its therapeutic effect?

What type of drug is defibrotide?

Defibrinoside/Defibrotide Sodium (DEFITELIO) is a drug containing the active substance defibrotide, which has a fibrinolytic effect and protects endothelial cells. It can increase fibrin lysis and regulate platelet activity to reduce procoagulant activity, and has a very good effect on hepatic veno-occlusive disease.

How effective is defibrotide treatment?

A European research group (including 19 treatment centers) reported the efficacy of defibrotide in 40 patients with hepatic veno-occlusive disease, 28 of whom were patients with severe hepatic veno-occlusive disease or multiple organ failure. The dosage of defibrotide is 10~40 mg/kg/d, the median application time is 18 days, and the median time of starting medication is +14 (-2+53) days after transplantation. The results showed that 22 cases (55%) had complete remission, and 17 cases (43%) survived beyond 100 days.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: